Bristol-Myers Squibb Company
Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer

Abstract:

There are disclosed compounds of formula (I) that modulate or inhibit the enzymatic activity of indoleamine-2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention. ##STR00001##